Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
World Health Organisation Regional Office for the Eastern Mediterranean, Cairo, Egypt.
BMJ Open. 2022 Feb 28;12(2):e054120. doi: 10.1136/bmjopen-2021-054120.
Urine pregnancy tests are often inaccessible in low-income settings. Expanded provision of home pregnancy testing could support self-care options for sexual and reproductive health and rights. We conducted a systematic review of pregnancy self-testing effectiveness, values and preferences and cost.
Systematic review and meta-analysis using the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach.
PubMed, CINAHL, LILACS and EMBASE and four trial registries were searched through 2 November 2020.
We included trials and observational studies that compared urine self-testing for pregnancy to health worker-led pregnancy testing on effectiveness outcomes; quantitative and qualitative studies describing values and preferences of end users and health workers and costs of pregnancy self-testing.
Two independent reviewers used standardised methods to search, screen and code included studies. Risk of bias was assessed using the Cochrane Collaboration and Evidence Project tools. Meta-analysis was conducted using random effects models. Findings were summarised in GRADE evidence profiles and synthesised qualitatively.
For effectiveness, four randomised trials following 5493 individuals after medical abortion showed no difference or improvements in loss to follow-up with home pregnancy self-testing compared with return clinic visits. One additional trial of community health workers offering home pregnancy tests showed a significant increase in pregnancy knowledge and antenatal counselling among 506 clients. Eighteen diverse values and preferences studies found support for pregnancy self-testing because of quick results, convenience, confidentiality/privacy, cost and accuracy. Most individuals receiving pregnancy self-tests for postabortion home management preferred this option. No studies reported cost data.
Pregnancy self-testing is acceptable and valued by end users. Effectiveness data come mostly from articles on postabortion care, and cost data are lacking. Greater availability of pregnancy self-tests, including in postabortion care and CHW programs, may lead to improved health outcomes.
CRD42021231656.
在低收入环境中,尿液妊娠检测往往无法获得。扩大家庭妊娠检测的提供范围,可以为性健康和生殖健康及权利的自我保健选择提供支持。我们对妊娠自我检测的效果、价值和偏好以及成本进行了系统评价。
使用推荐评估、发展和评估(GRADE)方法进行系统评价和荟萃分析。
通过 2020 年 11 月 2 日检索PubMed、CINAHL、LILACS 和 EMBASE 以及四个试验注册处。
我们纳入了比较尿液自我妊娠检测与卫生工作者主导的妊娠检测效果的试验和观察性研究;描述最终用户和卫生工作者的价值和偏好以及妊娠自我检测成本的定量和定性研究。
两位独立审查员使用标准方法搜索、筛选和编码纳入的研究。使用 Cochrane 协作和证据项目工具评估偏倚风险。使用随机效应模型进行荟萃分析。使用 GRADE 证据概况总结发现,并进行定性综合。
在有效性方面,四项随机试验共纳入 5493 例药物流产后患者,结果显示,与返回诊所就诊相比,家庭妊娠自我检测并不会导致随访丢失率增加或改善。另外一项关于社区卫生工作者提供家庭妊娠检测的试验显示,在 506 名患者中,妊娠知识和产前咨询显著增加。18 项不同的价值和偏好研究发现,妊娠自我检测因为快速获得结果、方便、保密性/隐私、成本和准确性而受到支持。大多数接受流产后家庭管理的妊娠自我检测的个体更喜欢这种选择。没有研究报告成本数据。
妊娠自我检测被最终用户接受和重视。有效性数据主要来自于流产后护理方面的文章,且缺乏成本数据。更广泛地提供妊娠自我检测,包括在流产后护理和社区卫生工作者方案中,可能会改善健康结局。
PROSPERO 注册号:CRD42021231656。